Navigation Links
Plant-cell-produced technologies-cutting edge approach to bringing solutions to the market

Four months after the world's first vaccine made in plant cells has received regulatory approval in the US, Dow AgroSciences is organising a Science Conference in Brussels on 7 June 2006 in order to share this knowledge with European researchers, scientists, decision-makers and industry representatives.

The pioneering vaccine developed by Dow AgroSciences works against the Newcastle disease virus (NDV) in poultry. The latest technology could be applied quite quickly to other diseases - with avian flu a prime target. This approval represents an innovative milestone for the company and the industry.

The Dow AgroSciences Concert Plant-Cell-Produced System represents a new category of plant-made vaccines. This leading edge technology utilises plant cells instead of whole plants in a secure, bio-contained environment to produce vaccines. Because of this bio-contained production system, concerns and challenges associated with making vaccines in whole plants or food crops are eliminated. The Concert Plant-Cell-Produced System uses only the necessary parts of the disease causing agent to stimulate immunity in a manufacturing process that is totally free of animal components:"Being the first company to ever register a plant-made vaccine is another example of Dow AgroSciences' cutting edge approach to bringing highly novel and differentiated solutions to the market," said Jerome Peribere, Dow AgroSciences' president and CEO.

The conference on 7 June, entitled "Innovations in Biosciences for Animal and Human Health" will highlight major bioscience developments and scientific solutions that could prevent diseases and reduce animal and human health risks in Europe. Dow AgroSciences President and Chief Executive Officer Mr. Jerome A. Peribere will deliver a welcome address. Dow AgroSciences's R&D capability will be presented by Mr. Antonio Galindez, (Dow AgroSciences VicePresicent, Europe, Latin America, Pacific) and Mr. Dan Kittle (Dow AgroSciences Vi cePresicent, Research and Development). Dr. Maurice Lex (European Commission, DG Research) will open discussion on Science Policy and R&D collaboration under the Seventh Framework Programme (FP7) in the area of biosciences for animal and human health.

Two parallel seminars will examine innovative plant-cell technologies and will present the benefit of healthy oils for consumers, agriculture and the food industry. The conference will also explore R&D collaboration under the EU's Seventh Framework Programme (FP7) in the area of biosciences for animal and human health.

Science Conference "Innovations in Bioscience for Animal and Human Health":
Date: 7 June 2006
Time: 08:30-16:00
Location: Renaissance Hotel, Rue du Parnasse 19, 1050 Brussels, Belgium
Admission Free
Online registration and the detailed programme is available at: http://www.isc-europe.com/dasconference/registration.php


'"/>

Source:ISC


Related biology news :

1. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
2. MSI releases moleculizer - a new approach to simulation of intracellular biochemical networks
3. Stopping smallpox in its tracks: A new anti-viral approach
4. Building a protein name dictionary from full text: a machine learning term extraction approach
5. Rensselaer researchers develop approach that predicts protein separation behavior
6. Huntingtons cure in flies lays groundwork for broader treatment approaches
7. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
8. Vaginal gel may provide a new approach to HIV prevention
9. Clinical trial to test stem cell approach for children with brain injury
10. Study in Science holds promise for a new approach to drug therapy
11. U-M researchers take new approach to defeating Gram-negative bugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology: